benzoyl peroxide/clindamycin / Generic mfg. - LARVOL DELTA

Papulonecrotic Tuberculid as the Initial Manifestation of Lymph Node Tuberculosis (EADV 2025) - "An initial diagnosis of infectious folliculitis was considered, and treatment with oral doxycycline and topical clindamycin and benzoyl peroxide was initiated, resulting in only transient improvement. This case highlights a rare presentation of papulonecrotic tuberculid as the cutaneous manifestation of ganglionar tuberculosis. Diagnosis was made possible by combining clinical suspicion with histopathology and molecular techniques, particularly the identification of Mycobacterium tuberculosis DNA by PCR, despite negative cultures. Dermatologists play a crucial role in identifying systemic diseases based on cutaneous findings."

Dermatology • Immunology • Infectious Disease • Respiratory Diseases • Tuberculosis

Comparative efficacy of clindamycin phosphate with benzoyl peroxide versus clindamycin phosphate with adapalene in acne vulgaris: a systematic review and meta-analysis. (PubMed, Sci Rep) - "CLIN/BPO also resulted in fewer application site side effects (OR = 0.33, 95% CI: 0.23-0.47, p < 0.001). However, no significant differences were observed between the groups for reducing inflammatory (MD = 1.34,"

Clinical • Journal • Retrospective data • Review • Acne Vulgaris • Dermatology

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: May 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Acne Vulgaris

A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne. (PubMed, Skin Therapy Lett) - "Clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126) is a novel fixed-dose triad gel combination approved by the US FDA October 2023 and by Health Canada August 2024 for the treatment of acne vulgaris in patients aged 12 years and older...Efficacy outcomes were inflammatory and noninflammatory lesion counts and Evaluator's Global Severity Score. IDP-126 also had a favorable tolerability and safety profile."

Journal • Acne Vulgaris • Dermatology

Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity. (PubMed, Dermatol Ther (Heidelb)) - P2, P3 | "CAB demonstrated superior efficacy to three dyads and branded ADAP 0.3%/BPO 2.5% in moderate acne participants, and generally numerically greater efficacy in severe acne participants. To our knowledge, these analyses include data from the only double-blind, vehicle-controlled, head-to-head study."

Journal • Retrospective data • Acne Vulgaris

Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations in Combating Rising Resistance in Cutibacterium acnes. (PubMed, Clin Cosmet Investig Dermatol) - "All tested antibiotics (clindamycin, doxycycline, erythromycin, and minocycline) exhibited similar activity...Overall, antibiotic susceptibility was highly dependent on the C. acnes strain, and antibiotic formulations with BPO exhibited enhanced activity against less susceptible strains. Fixed combinations of BPO with an antibiotic may improve antimicrobial activity and protect against resistance development."

Journal • Acne Vulgaris

Assessing the Adherence and Clinical Outcomes of using Multiple Topical Acne Products vs a Single Combination Product (AAD 2025) - "They were randomized into 3 treatment arms: one receiving adapalene+benzoyl peroxide+clindamycin (one topical), one arm receiving adapalene + benzoyl peroxide and clindamycin gel (two topicals), and one arm receiving adapalene gel, benzoyl peroxide gel, and clindamycin gel (three topicals). Poor adherence to topical treatment is common in patients with acne. Simplifying the treatment regimen to a single product may improve adherence."

Adherence • Clinical • Clinical data • Acne Vulgaris • Dermatology

Prescribing patterns for treatment of acne vulgaris: A retrospective chart review at an urban public and private hospital. (PubMed, Arch Dermatol Res) - "Findings from this study highlight differences in acne prescribing patterns by race/ethnicity and hospital system, which can impact the ability of patients to have successful treatment of their acne and its sequelae."

Journal • Retrospective data • Acne Vulgaris • Dermatology

Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne. (PubMed, J Clin Aesthet Dermatol) - "This pilot evaluation, albeit small and open-label, demonstrates promising results for the first studied combination of topical agents to target all four aspects of acne pathophysiology. Further large-scale studies are needed to further elucidate the additive efficacy and side effect profile when these two topical medications are used concomitantly."

Journal • Acne Vulgaris • Dermatology • Inflammation

Novel Cationic Bolaamphiphiles for Protein and DNA Binding, Gene Delivery, and Antimicrobial Applications. (PubMed, Chem Asian J) - "The impact of head group structure on the self-assembly and effectiveness of gene transfection and antimicrobial activity was investigated and compared with that of the hydrochloride salt C12-(N, N-dimethyl-N-(2-ureidoethan-1-aminium chloride)2 (C12(DUAC)2) of its precursor molecule...MTT-based in vitro cytotoxicity assay was performed and both bolaforms were found to have marginal cytotoxicity. Further, both bolaforms exhibit advantageous antibacterial activity against E. coli and potent antifungal activity against Fusarium oxysporum at high dosages."

Journal

Triple Therapy IDP-126 Gel for Acne Treatment: A Systematic Review and Meta-Analysis. (PubMed, Cureus) - "The recent FDA approval of IDP-126 (Cabtreo™), a novel triple-combination gel, meets these needs by combining clindamycin phosphate, benzoyl peroxide, and adapalene into a single formulation. IDP-126 is an effective treatment for AV, offering substantial clinical benefits and improving quality of life. While it is associated with higher rates of certain adverse effects, its overall efficacy supports its inclusion in treatment regimens, provided that its safety profile is carefully managed to optimize patient outcomes."

Journal • Retrospective data • Review • Acne Vulgaris • Dermatology • Pain

Efficacy and safety of the novel clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15%. triple combination in treating acne: systematic review and meta-analysis. (PubMed, Arch Dermatol Res) - No abstract available

Journal • Retrospective data • Review • Acne Vulgaris

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Wake Forest University Health Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Acne Vulgaris

Topical, light-based, and complementary interventions for acne: an overview of systematic reviews. (PubMed, Cochrane Database Syst Rev) - "This overview summarises the evidence for topical therapy, phototherapy, and complementary therapy for acne and acne scars. We found no high-certainty evidence for the effects of any therapy included. Randomised controlled trials and systematic reviews related to acne and acne scars had limitations (low methodological quality). We could not summarise the evidence for topical retinoids and topical antibiotics due to insufficient high-quality systematic reviews. Future research should consider pooled analysis of data on new emerging drugs for acne treatment (e.g. clascoterone) and focus more on acne complications."

Clinical • Journal • Review • Acne Vulgaris • Dermatology

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne (clinicaltrials.gov) - P4 | N=10 | Completed | Sponsor: Sun Pharmaceutical Industries Limited | Active, not recruiting ➔ Completed

Trial completion • Acne Vulgaris • Dermatology

Jak Inhibitor in a Refractory Case of penile HS (EADV 2024) - "First line of treatment included PO clindamycin, topical clindamycin, and benzoyl peroxide 10% solution...Therapy was escalated to 1cc of intralesional kenalog-10 injected into each lesion, moxifloxacin 400 mg daily, metronidazole 500 mg TID, and rifampin 300 mg BID along with topicals due to increased serosanguinous discharge from the area along with fever, tachycardia, and leukocytosis. As he was still not improving, the patient was then started on the biologic adalimumab, a TNF blocker...The patient failed several additional treatments including PO steroids, IV ertapenem, and seculuzimab (IL-17A inhibitor) . He was also poorly controlled on infliximab (TNF alpha inhibitor) even when maxing out the infliximab dose to 10 mg/kg q4 weeks. Due to complications and poor control of HS in this patient, he will now be started on Tofacitinib (Jak inhibitor) in addition to a TNF alpha inhibitor for greater benefit. Additionally, cyclosporine was used as an off-label treatment to..."

Clinical • Cardiovascular • Dermatology • Hidradenitis Suppurativa • Pain • IL17A

Plant Phenolics in the Prevention and Therapy of Acne: A Comprehensive Review. (PubMed, Molecules) - "It was revealed that because of their significant antibacterial, anti-inflammatory and antioxidant activities, phenolic compounds may be used in the treatment of various types of acne, individually as well as in combination with commonly used drugs like clindamycin and benzoyl peroxide. Among the various phenolics that have been tested, EGCG, quercetin and nobiletin seem to be the most promising ones; however, more studies, especially clinical trials, are needed to fully evaluate their efficacy in treating acne."

Journal • Review • Acne Vulgaris • Dermatology • Rosacea

Letter to the editor: comparative efficacy and safety of clindamycin phosphate/benzoyl peroxide and adapalene/benzoyl peroxide in acne treatment: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Arch Dermatol Res) - No abstract available

Clinical • Journal • Retrospective data • Review • Acne Vulgaris

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: May 2025 ➔ Nov 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Adherence • Trial completion date • Trial primary completion date • Acne Vulgaris

Updates on Topical Dyad and Triple Combination Therapies Approved for Acne Vulgaris. (PubMed, Cureus) - "It was found that various topical dyad and triad combinations exist for acne vulgaris, including adapalene/BPO, tazarotene/clindamycin, clindamycin/BPO, adapalene/clindamycin, topical tretinoin/azelaic acid, topical tretinoin/BPO, and clindamycin phosphate/benzoyl peroxide/adapalene. Clindamycin phosphate/benzoyl peroxide/adapalene exhibited significantly high efficacy in treating both inflammatory and noninflammatory lesions, a minimal side effect profile, although no significant changes in quality-of-life measures. Further research is indicated to assess its long-term efficacy and impact on other acne metrics such as cost, scarring, psychosocial implications, and impact on diverse patient populations."

Combination therapy • Journal • Review • Acne Vulgaris • Dermatology

Cabtreo: A three-drug gel for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne (clinicaltrials.gov) - P4 | N=10 | Active, not recruiting | Sponsor: Sun Pharmaceutical Industries Limited

New P4 trial • Acne Vulgaris • Dermatology

Therapeutic project of 210 HS patients from the official registry of "Andreas Sygros" Hospital for Venereal and Cutaneous Diseases(#164) (EHSF 2024) - "As far as topical therapy is concerned, 52.3% was treated with octenidine soap, 59.8% with gel clindamycin/benzoyl peroxide (BPO), 22% with topical clindamycin and 6.1% with topical corticosteroids...From those receiving antibiotics, the 52.4% had received tetracyclines (doxycycline), 29.3% the combined antibiotic therapy with rifampicin and clindamycin and 6.1% penicillin/clavulanic acid...Of the patients receiving anti-IL17, 86.7% received secukinumab and 13.3% bimekizumab. CONCLUSIONS According to the data from the official HS Registry of "Andreas Sygros" Hospital, regarding the first 210 patients registered, it is underlined that the most common treatments include local treatment, mainly octenidine and BPO, as well as systemic treatment with antibiotics, such as doxycycline and rifampicin/clindamycin. Finally, the use of adalimumab ranges at high rates, while the administration of anti-IL17 is still in its infancy."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation

Systematic Literature Review and Network Meta-Analysis to Assess the Comparative Efficacy of Topical Fixed-Dose Combinations for Moderate to Severe Acne Vulgaris as Measured By Lesion Counts (ISPOR-EU 2023) - "Based on the findings from this SLR/NMA, IDP-126 topical gel (currently under FDA review; PDUFA date 20 October 2023), was clinically superior to all other topical FDC treatments in reducing acne lesions in the patients with moderate to severe acne vulgaris."

Retrospective data • Review • Acne Vulgaris • Dermatology

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Sep 2024 ➔ Dec 2024

Adherence • Trial completion date • Acne Vulgaris